Abstract: A method of selecting a semaphorin for treating cancer in a subject is disclosed. The method comprises determining an expression of a semaphorin receptor on tumor cells of a tumor sample of the subject wherein an amount of the semaphorin receptor is indicative of the semaphorin suitable for treating the cancer in the subject. Methods of treating angiogenesis, kits for treating cancer and pharmaceutical compositions comprising semaphorins are also disclosed.
Type:
Application
Filed:
December 7, 2011
Publication date:
April 26, 2012
Applicant:
Rappaport Family Institute for Research in the Medical Sciences
Inventors:
Gera Neufeld, Boaz Kigel, Ofra Kessler, Asya Varshavsky
Abstract: Propargylamine, propargylamine derivatives including N-propargyl-l-aminoindan, enantiomers and analogs thereof, and pharmaceutically acceptable salts thereof, are useful for prevention or treatment of cardiovascular disorders, diseases and conditions.
Type:
Application
Filed:
December 23, 2011
Publication date:
April 19, 2012
Applicants:
RAPPAPORT FAMILY INSTITUTE FOR RESEARCH IN THE MEDICAL SCIENCES, TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD.
Abstract: Propargylamine, propargylamine derivatives including N-propargyl-1-aminoindan, enantiomers and analogs thereof, and pharmaceutically acceptable salts thereof, are useful for prevention or treatment of cardiovascular disorders, diseases and conditions.
Type:
Grant
Filed:
June 9, 2006
Date of Patent:
January 17, 2012
Assignees:
Technion Research and Development Foundation Ltd., Rappaport Family Institute
Inventors:
Moussa B. H. Youdim, Ofer Binah, Zaid A. Abassi, Yaron Barac
Abstract: Provided are methods and kits for determining predisposition of a subject to develop a kidney disease, by identifying in a sample of the subject at least one APOL1 polypeptide variant which is characterized by a higher trypanolytic activity on Trypanosoma brucei rhodesiense as compared to the trypanolytic activity of wild type APOL1 polypeptide as set forth in SEQ ID NO:1 on the Trypanosoma brucei rhodesiense under identical assay conditions; or at least one APOL1 nucleotide mutation in the APLO1 genomic sequence set forth in SEQ ID NO:3, wherein the at least one nucleotide mutation or polypeptide variant being in linkage disequlibrium (LD) with the S342G mutation in the APOL1 polypeptide set forth in SEQ ID NO:1, wherein presence of the APOL1 polypeptide variant indicates increased predisposition of the subject to develop the kidney disease.
Type:
Application
Filed:
June 6, 2011
Publication date:
January 5, 2012
Applicant:
Rappaport Family Institute for Research in the Medical Sciences
Inventors:
Karl Skorecki, Shay Tzur, Saharon Rosset, Walter Gabriel Wasser, Doron M. Behar, Revital Shemer
Abstract: A method of selecting a semaphorin for treating cancer in a subject is disclosed. The method comprises determining an expression of a semaphorin receptor on tumor cells of a tumor sample of the subject wherein an amount of the semaphorin receptor is indicative of the semaphorin suitable for treating the cancer in the subject. Methods of treating angiogenesis, kits for treating cancer and pharmaceutical compositions comprising semaphorins are also disclosed.
Type:
Grant
Filed:
October 2, 2008
Date of Patent:
January 3, 2012
Assignee:
Rappaport Family Institute for Research in the Medical Sciences
Inventors:
Gera Neufeld, Boaz Kigel, Ofra Kessler, Asya Varshavsky
Abstract: A method of reducing an inflammatory response in a subject is provided. The method comprising providing to a subject in need thereof a therapeutically effective amount of an agent capable of reducing activity and/or expression of a scavenger receptor or of an effector thereof, thereby reducing the inflammatory response in the subject.
Type:
Application
Filed:
August 9, 2011
Publication date:
November 24, 2011
Applicant:
Rappaport Family Institute for Research in the Medical Sciences
Abstract: A method of reducing an inflammatory response in a subject is provided. The method comprising providing to a subject in need thereof a therapeutically effective amount of an agent capable of reducing activity and/or expression of a scavenger receptor or of an effector thereof, thereby reducing the inflammatory response in the subject.
Type:
Application
Filed:
August 9, 2011
Publication date:
November 24, 2011
Applicant:
Rappaport Family Institute for Research in the Medical Sciences
Abstract: A method of reducing an inflammatory response in a subject is provided. The method comprising providing to a subject in need thereof a therapeutically effective amount of an agent capable of reducing activity and/or expression of a scavenger receptor or of an effector thereof, thereby reducing the inflammatory response in the subject.
Type:
Grant
Filed:
September 12, 2005
Date of Patent:
September 13, 2011
Assignee:
Rappaport Family Institute for Research in the Medical Sciences
Abstract: Provided are methods of regulating keratinocytes proliferation and differentiation by subjecting keratinocytes to an agent capable of modulating activity or expression of IGFBP7, thereby regulating keratinocytes proliferation and differentiation. Also provided are methods of treating pathologies characterized by hyperproliferative keratinocytes by administering IGFBP7 polypeptide or a polynucleotide encoding IGFBP7 polypeptide to a subject.
Type:
Application
Filed:
February 28, 2010
Publication date:
August 25, 2011
Applicants:
THE MEDICAL RESEARCH, INFRASTRUCTURE AND HEALTH SE, RAPPAPORT FAMILY INSTITUTE FOR RESEARCH IN THE MED
Abstract: An isolated polypeptide is provided. The polypeptide comprising an antigen recognition domain capable of specifically binding a human scavenger receptor, wherein the antigen recognition domain comprises at least three CDR amino acid sequences selected from the group consisting of SEQ ID NO: 11, 15, 19, 23, 27 and 31. Also provided are compositions which comprise the peptide and uses of same.
Type:
Application
Filed:
September 11, 2006
Publication date:
August 4, 2011
Applicant:
Rappaport Family institute for Research in the Medical Sciences
Abstract: A method of treating Multiple Sclerosis is disclosed. The method comprises administering to the subject a therapeutically effective amount of SDF-1 alpha. An article of manufacture comprising SDF-1 alpha and an anti-Multiple Sclerosis agent is also disclosed.
Type:
Application
Filed:
February 6, 2008
Publication date:
February 24, 2011
Applicant:
Rappaport Family Institute for Research in the Medical Sciences
Abstract: The present applications describes, inter alia, a retinal light management system that allows for removal of dangerous wavelengths of light while controlling the intensity of the remaining light that is allowed to pass to a user's eyes. In one embodiment, the system involves a pair of glasses that include filters that can be modified in the presence of light to reduce total light intensity reaching a diabetic's eyes.
Type:
Application
Filed:
July 20, 2008
Publication date:
November 4, 2010
Applicant:
Rappaport Family Institute for Research in the Medical Sciences
Abstract: A method of treating prostate cancer is provided. The method comprising administering to a subject in need thereof a therapeutically effective amount of an agent capable of reducing activity and/or expression of MCP-1 or of an effector thereof, thereby treating the prostate cancer in the subject.
Type:
Application
Filed:
May 24, 2010
Publication date:
October 14, 2010
Applicant:
Rappaport Family Institute for Research in the Medical Sciences
Abstract: A method of selecting a semaphorin for treating cancer in a subject is disclosed. The method comprises determining an expression of a semaphorin receptor on tumor cells of a tumor sample of the subject wherein an amount of the semaphorin receptor is indicative of the semaphorin suitable for treating the cancer in the subject. Methods of treating angiogenesis, kits for treating cancer and pharmaceutical compositions comprising semaphorins are also disclosed.
Type:
Application
Filed:
October 2, 2008
Publication date:
September 30, 2010
Applicant:
Rappaport Family Institute for Research Research in the Medical Sciences
Inventors:
Gera Neufeld, Boaz Kigel, Ofra Kessler, Asya Varshavsky
Abstract: Soluble molecules are provided. Thus, for example, provided is a soluble molecule which comprises a heterologous amino acid sequence conjugated to a CCR5 amino acid sequence being capable of binding a CCR5 ligand, and wherein the molecule is devoid of an N-terminus domain of CCR5. Also provided are pharmaceutical compositions which comprise the above molecules and methods and uses of same.
Type:
Application
Filed:
February 18, 2007
Publication date:
September 9, 2010
Applicant:
Rappaport Family Institute for Research in the Medical Sciences
Abstract: An amino acid sequence derived from the N? terminus region of the 50 Kd subunit of heparanase, preferably, the sequence including amino acid residues Lys158-Asn171 of human heparanase and any functional fragments thereof. Compositions for the inhibition of heparanase glycosidase catalytic activity, having as an active ingredient an isolated and purified peptide as the amino acid sequence. An antibody directed to the sequence and compositions and uses thereof as heparanase inhibitor. The use of the amino acid sequence in a screening method for specific heparanase inhibitors. Compositions including the heparanase inhibitors and methods for the treatment of heparanase related disorders.
Type:
Grant
Filed:
July 28, 2004
Date of Patent:
August 10, 2010
Assignees:
Hadasit Medical Research Services and Development Company, Ltd., Rappaport Family Institute for Research in the Medical Sciences
Inventors:
Israel Vlodavsky, Neta Ilan, Flonia Levy-Adam
Abstract: A method of treating an autoimmune disease such as Multiple Sclerosis is disclosed. The method comprises administering to a subject a therapeutically effective amount of CXCL11. Polypeptides and pharmaceutical compositions for treating same are also disclosed.
Type:
Application
Filed:
June 4, 2008
Publication date:
August 5, 2010
Applicant:
Rappaport Family Institute for Research in the Medical Sciences
Abstract: A method of treating prostate cancer is provided. The method comprising administering to a subject in need thereof a therapeutically effective amount of an agent capable of reducing activity and/or expression of MCP-1 or of an effector thereof, thereby treating the prostate cancer in the subject.
Type:
Grant
Filed:
March 14, 2004
Date of Patent:
July 6, 2010
Assignee:
Rappaport Family Institute for Research in the Medical Sciences
Abstract: Methods and kits for diagnosing a lipid-related disorder are disclosed. Methods and pharmaceutical compositions for treating lipid-related disorders are also disclosed.
Type:
Application
Filed:
March 18, 2007
Publication date:
February 4, 2010
Applicant:
Rappaport Family Institute Research in the Medical Sciences
Inventors:
Leonid Gaydukov, Olga Khersonsky, Dan S. Tawfik, Michael Aviram